Subject to change.
Subject to change.
Mark is a Senior Director of Computational Pathology at AstraZeneca where he leads teams delivering next-generation computational pathology approaches. Prior to that, he was part groups delivering Biomarkers and Companion Diagnostics. Before AstraZeneca, Mark worked at the FDA as well as various computational pathology companies. Mark received his Ph.D. in Cancer Biology from Vanderbilt University and did his post-doctoral fellowship under Dr. David Rimm at Yale University.